

1/52

FIG. 1






FIG. 2



2/52

FIG. 3

Rapamycin Release from VDF/HFP (84.5/14.5) in
25% EtOH



3/52

FIG. 4

Release in 25% Aq. Ethanol for
21508 + Rapamycin w/ top coat




FIG. 5
Release of Drug from FC-2261Q





FIG. 6



6/52

FIG. 7




FIG. 8





FIG. 9



7/52

FIG. 10





FIG. 11



8/52

FIG. 12





FIG. 13



9/52

FIG. 14




FIG. 15





FIG. 16



10/52

FIG. 17




FIG. 18





FIG. 19



11/52

FIG. 20




FIG. 21




FIG. 22




FIG. 23





FIG. 24



14/52

FIG. 25







FIG. 26





16/52

FIG. 28



18/52

FIG. 30




FIG. 31





FIG. 32



19/52

FIG. 33




FIG. 34




FIG. 35





FIG. 36



21/52

FIG. 37





FIG. 38



22/52

FIG. 39




FIG. 40




FIG. 41




FIG. 42






FIG. 43





24/52

FIG. 45





FIG. 46



25/52

FIG. 47




FIG. 48






FIG. 49




27/52

FIG. 50



28/52

FIG. 51



29/52

FIG. 52





FIG. 53



31/52

FIG. 54




FIG. 55




FIG. 56





FIG. 57



35/52

FIG. 58




FIG. 59





FIG. 60



38/52

FIG. 61




FIG. 62




FIG. 63




FIG. 64

Inhibition of CA-SMC proliferation by
sirolimus and topotecan (14 April 2003)





FIG. 65


Inhibition of CA-SMC proliferation by
sirolimus and etoposide (14 April 2003)



43/52

FIG. 66


Inhibition of CA-SMC proliferation by
Panzem



44/52

FIG. 67

Inhibition of CA-SMC
proliferation by sirolimus



45/52

FIG. 68

Inhibition of CA-SMC proliferation by
 Sirolimus and Panzem






FIG. 69




47/52

FIG. 70



48/52

FIG. 71



49/52

FIG. 72A




FIG. 72B





FIG. 72C



50/52

FIG. 73A





FIG. 73B



51/52

FIG. 74




FIG. 75

